Chohreh Partovian, MD, PhD
August 18th, 2013
What Patterns of Change in the Use of Nesiritide Reveal About Hospitals as Learning Organizations
Chohreh Partovian, MD, PhD
Chohreh Partovian discusses her research group’s study of how hospitals varied in their responses to safety concerns about nesiritide from 2005 to 2010.
July 25th, 2012
DES in Patients at Low Risk for TVR: Is the Benefit Worth the Cost? (Part I)
Gregg W Stone, MD, John A. Bittl, M.D., David Kandzari, MD, Richard A. Lange, MD, MBA and L. David Hillis, MD
In a recent article in Archives of Internal Medicine, researchers performed an analysis of current use of drug-eluting stents (DES) in patients at various levels of risk for target-vessel revascularization (TVR), and estimated the cost and clinical outcomes of using BMS rather than DES in patients at low risk (see News). To gauge reaction to […]
April 24th, 2012
Primary PCI Meta-Analysis: Mortality Trumps All
Chohreh Partovian, MD, PhD
In a new meta-analysis Dr. Gregg Stone and members of the Drug-Eluting Stent in Primary Angioplasty (DESERT) Cooperation concluded that reduction in target-vessel revascularization (TVR) associated with drug-eluting stents (DES) in primary PCI provided a powerful reason for continued use of DES in primary PCI. An accompanying editorial by James Brophy focused on several potential DES weaknesses in the study. […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?